All
Below you can find a link with presentation published by the magazine DECIDEURS about Blue Forward Fund™
Launched in December 2021 by Seventure Partners , Blue Forward Fund™ is the first European fund dedicated to blue economy...
Galecto announces first patient enrolled in phase 2 trial of GB1211 in combination with Atezolizumab for first-line treatment of NSCLC
GB1211, Galecto's galectin-3 inhibitor, has shown potent anti-tumor effects and increased efficacy of checkpoint inhibition in pre-clinical models
Enterome presents proof-of-concept immune response data and first clinical data from Phase 1/2 trial with EO2401, a first-in-class OncoMimics™ therapeutic cancer vaccine for adrenocortical carcinoma, at ASCO 2022
Enterome, a clinical stage biopharmaceutical company developing first-in-class immunomodulatory drugs based on its bacterial Mimicry drug discovery platform, today announces...
Enterome presents proof-of-concept immune response data and first clinical data from Phase 1/2 trial with EO2401, a first-in-class OncoMimics™ therapeutic cancer vaccine for glioblastoma, at ASCO 2022
Enterome, a clinical stage biopharmaceutical company developing first-in-class immunomodulatory drugs based on its bacterial Mimicry drug discovery platform, today announces...
MaaT Pharma Confirms Positive Results from Completed Phase 1b CIMON Study Evaluating MaaT033 in Blood Cancer Patients
MaaT Pharma (EURONEXT: MAAT – the “Company”), a French clinical-stage biotech and a pioneer in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to...
Dermala, a consumer dermatology company, announces their second microbiome-powered line of topical and oral products for eczema-prone skin
DERMALA, the only personalized, clinically proven treatment for acne powered by the human microbiome, extends its product range to include a second microbiome-powered line of...
Vedanta Presents Data from Multiple Studies at Digestive Disease Week 2022 Annual Meeting
Vedanta Biosciences, a clinical-stage biopharmaceutical company pioneering the development of oral therapies based on defined bacterial consortia, today announced the details...
Tubulis Closes €60 Million Series B Financing to Accelerate its ADC Pipeline and Expand its Breadth of Platform Technologies
Tubulis today announced the successful completion of a €60 million (USD $63 million) Series B financing led by Andera Partners with participation from new investors Evotec...
INRAE and MaaT Pharma Build on the Success of their Long-Standing Partnership with the Entry of Drug-Candidate MaaT013 into Phase 3 Clinical Trial
MaaT Pharma (EURONEXT: MAAT – the “Company”), a French clinical-stage biotech and a pioneer in the development of microbiome-based ecosystem therapies dedicated to...